115 related articles for article (PubMed ID: 20977850)
1. [Comparison of therapeutic efficacy between fondaparinux and low molecular weight heparin for patients with acute coronary syndrome].
Wang QK; Guo M; Zhang YQ; Song Y
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Oct; 22(10):628-31. PubMed ID: 20977850
[TBL] [Abstract][Full Text] [Related]
2. Factor Xa inhibitors for acute coronary syndromes.
Brito V; Ciapponi A; Kwong J
Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
[TBL] [Abstract][Full Text] [Related]
3. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.
Szummer K; Oldgren J; Lindhagen L; Carrero JJ; Evans M; Spaak J; Edfors R; Jacobson SH; Andell P; Wallentin L; Jernberg T
JAMA; 2015 Feb; 313(7):707-16. PubMed ID: 25688782
[TBL] [Abstract][Full Text] [Related]
4. Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis.
Qiao J; Zhang X; Zhang J; Li P; Xu B; Wang S; Jiang H; Shen Y; Wang K
Cardiology; 2016; 133(3):163-72. PubMed ID: 26605908
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of bridging therapy with fondaparinux versus low-molecular-weight heparin in patients undergoing atrial fibrillation ablation.
Zhang F; Zhao D; Peng X; Yang H; Zhu T; Huang F; Peng J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):448-52. PubMed ID: 24752085
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inactivation in acute coronary syndrome.
Barantke M; Bonnemeier H
Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
[TBL] [Abstract][Full Text] [Related]
8. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
Bundhun PK; Shaik M; Yuan J
BMC Cardiovasc Disord; 2017 May; 17(1):116. PubMed ID: 28482804
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of platelet monitoring in patients receiving thromboprophylaxis with fondaparinux or a low molecular weight heparin. The Ariane study].
Gouin-Thibault I; Liard F; Van-Ganse E; Vespa L; Gaudin AF; Nachit-Ouinekh F
Presse Med; 2011 Sep; 40(9 Pt 1):e365-75. PubMed ID: 21515025
[TBL] [Abstract][Full Text] [Related]
10. Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes.
Yan HB; Song L; Liu R; Zhao HJ; Wang SP; Chi YP; Zheng B; Li WZ; Liu C; Zhou P
Chin Med J (Engl); 2011 Mar; 124(6):879-86. PubMed ID: 21518596
[TBL] [Abstract][Full Text] [Related]
11. Which heparin and how much?
Ruchin PE; Labinaz M
Curr Cardiol Rep; 2008 Jul; 10(4):312-8. PubMed ID: 18611366
[TBL] [Abstract][Full Text] [Related]
12. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on fondaparinux sodium in acute coronary syndromes.
Blick SK; Orman JS; Wagstaff AJ; Scott LJ
BioDrugs; 2008; 22(6):413-5. PubMed ID: 18998758
[TBL] [Abstract][Full Text] [Related]
15. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
16. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
; Steg PG; Jolly SS; Mehta SR; Afzal R; Xavier D; Rupprecht HJ; López-Sendón JL; Budaj A; Diaz R; Avezum A; Widimsky P; Rao SV; Chrolavicius S; Meeks B; Joyner C; Pogue J; Yusuf S
JAMA; 2010 Sep; 304(12):1339-49. PubMed ID: 20805623
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
